治疗对中轴型脊柱关节炎放射学进展的影响:系统评价与荟萃分析
结果显示TNFi治疗2年及≥4年与生物制剂初治患者mSASSS差异无统计学意义,但低偏倚风险研究亚组分析显示≥4年TNFi治疗有显著保护作用。NSAIDs和司库奇尤单抗治疗2年未见显著差异。
要点
- TNFi治疗2年及≥4年整体未显著减缓脊柱放射学进展。
- 低偏倚风险研究显示TNFi治疗≥4年可显著减缓mSASSS进展。
- NSAIDs或司库奇尤单抗治疗2年未见放射学进展显著差异。
核心结论
- 整体分析未显示TNFi对中轴型脊柱关节炎患者2年或≥4年脊柱放射学进展有显著保护作用。
- 限制于低偏倚风险研究的分析显示TNFi治疗≥4年对脊柱放射学进展有保护作用(mSASSS差异-2.17,95%CI -4.19至-0.15)。
- NSAIDs或司库奇尤单抗治疗2年与对照相比放射学进展无显著差异。
研究设计与样本
- 系统评价与荟萃分析,检索评估中轴型脊柱关节炎放射学进展的研究,比较特定治疗与无该治疗。
- 采用随机效应模型合并治疗结局在2年和≥4年的标准化均数差。
主要发现
- TNFi治疗2年与生物制剂初治患者mSASSS差异为-0.73(95%CI -1.52至0.12,I2=28%),无显著差异。
- TNFi治疗≥4年与生物制剂初治患者mSASSS差异为-2.03(95%CI -4.63至0.72,I2=63%),无显著差异。
- 低偏倚风险研究亚组分析中,TNFi治疗≥4年mSASSS差异为-2.17(95%CI -4.19至-0.15),有显著差异。
- NSAIDs治疗与对照的mSASSS差异为-0.30(95%CI -2.62至1.31,I2=71%),无显著差异。
- 司库奇尤单抗治疗与生物制剂初治患者的mSASSS差异为-0.34(95%CI -0.85至0.17),无显著差异。
关键数值与推荐
- 放射学进展采用改良Stoke强直性脊柱炎脊柱评分(mSASSS)测量。
- 非放射学中轴型脊柱关节炎患者或采用骶髂关节评分测量放射学进展的研究数量不足,无法分析。
临床怎么用
- 长期TNFi暴露可能对中轴型脊柱关节炎患者脊柱放射学进展有益,尤其基于低偏倚风险研究证据。
- NSAIDs或司库奇尤单抗治疗2年对放射学进展的影响未见显著差异。
- 未来需研究中轴型脊柱关节炎早期或非放射学患者生物制剂治疗及长期暴露对放射学进展的影响。
局限性
- 非放射学中轴型脊柱关节炎和骶髂关节评分相关研究数量不足,无法分析。
- 部分合并分析存在异质性(如TNFi≥4年I2=63%,NSAIDs I2=71%)。
- 整体TNFi分析未显示显著保护作用,仅低偏倚风险研究亚组显示≥4年有显著效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the effect of therapies on radiographic progression in patients with axial spondyloarthritis (SpA). METHODS: A comprehensive database search for studies assessing radiographic progression in axial SpA (particular treatment versus no treatment of interest) was performed. Study-specific standardized mean differences in treatment outcomes at 2 and ≥4 years were estimated and combined using random-effects models. RESULTS: Twenty-four studies in patients with axial SpA were identified, of which 18 involved tumor necrosis factor inhibitors (TNFi), 8 involved nonsteroidal antiinflammatory drugs (NSAIDs), and 1 involved secukinumab. Spinal radiographic progression, as measured by the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS), was not significantly different between TNFi-treated and biologics-naive patients at 2 years (mSASSS difference -0.73 [95% confidence interval (95% CI) -1.52, 0.12], I2 = 28%) and ≥4 years (mSASSS difference -2.03 [95% CI -4.63, 0.72], I2 = 63%). Sensitivity analyses restricted to studies with a low risk of bias showed a significant difference in spinal radiographic progression between TNFi-treated and biologics-naive patients at ≥4 years (mSASSS difference -2.17 [95% CI -4.19, -0.15]). No significant difference in spinal radiographic progression was observed between NSAID-treated and control patients (mSASSS difference -0.30 [95% CI -2.62, 1.31], I2 = 71%) or between secukinumab-treated and biologics-naive patients (mSASSS difference -0.34 [95% CI -0.85, 0.17]). With regard to treatment differences in patients with nonradiographic axial SpA or in patients with radiographic progression measured using the sacroiliac joint score, an insufficient number of studies were available for analysis. CONCLUSION: Although no significant protective effect of TNFi treatment on spinal radiographic progression was seen over the course of 2 years or ≥4 years in patients with axial SpA, our analysis restricted to studies with a low risk of bias showed a protective effect of TNFi after ≥4 years. Therefore, long-term TNFi exposure might confer beneficial effects on spinal radiographic progression in axial SpA. No difference in radiographic progression at 2 years was seen in either the NSAID or secukinumab treatment groups compared to their controls. Future studies should explore the effects of biologic treatment on radiographic progression, as well as the effects of long-term biologics exposure, in patients with early axial SpA or those with nonradiographic axial SpA.
引用
- Karmacharya P, Duarte-Garcia A, Dubreuil M, et al. Effect of Therapy on Radiographic Progression in Axial Spondyloarthritis: A Systematic Review and Meta-Analysis. Arthritis Rheumatol. 2020. PMID: 31960614. doi:10.1002/art.41206
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。